Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss

Description

This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.

Conditions

Obesity and Obesity-related Medical Conditions

Talk to us

Study Overview

On this page

Study Details

Study overview

This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.

Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss

Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss

Condition
Obesity and Obesity-related Medical Conditions
Intervention / Treatment

-

Contacts and Locations

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult 18 to 65 years of age
  • * Body Mass Index \>35 with comorbidity of Type 2 Diabetes and/or Hypertension and/or Hyperlipidemia and/or Obstructive Sleep Apnea OR Body Mass Index \>40 with or without comorbidity
  • * Undergoing primary sleeve gastrectomy
  • * Prior metabolic and bariatric surgery
  • * Prior use of GLP-1 agonist
  • * Prior history of pancreatitis
  • * Personal/family history of medullary thyroid cancer or MEN type 2
  • * Secondary cause of obesity
  • * Any eating disorder
  • * Pregnancy/lactation
  • * History of acute coronary syndrome or myocardial infarction
  • * History of stroke
  • * Hepatic dysfunction: AST/ALT \>3 ULN
  • * Renal dysfunction eGFR\<45ml/min/1.73m2
  • * Active malignancy
  • * History of diabetic retinopathy
  • * History of gastroparesis

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Nicholas Skertich,

Nicholas Skertich, MD, PRINCIPAL_INVESTIGATOR, Rush University Medical Center

Study Record Dates

2028-02